Patient‐reported outcome measures (PROMs): a review of generic and condition‐specific measures and a discussion of trends and issues

K Churruca, C Pomare, LA Ellis, JC Long… - Health …, 2021 - Wiley Online Library
Background Patient‐reported outcome measures (PROMs) are questionnaires that collect
health outcomes directly from the people who experience them. This review critically …

Non-small-cell lung cancer

C Gridelli, A Rossi, DP Carbone, J Guarize… - Nature reviews Disease …, 2015 - nature.com
Lung cancer is one of the most frequently diagnosed cancers and is the leading cause of
cancer-related death worldwide. Non-small-cell lung cancer (NSCLC), a heterogeneous …

[HTML][HTML] Brigatinib versus crizotinib in ALK inhibitor–naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial

DR Camidge, HR Kim, MJ Ahn, JCH Yang… - Journal of Thoracic …, 2021 - Elsevier
Introduction In the phase 3 study entitled ALK in Lung cancer Trial of brigAtinib in 1st Line
(ALTA-1L), which is a study of brigatinib in ALK inhibitor–naive advanced ALK-positive …

Brigatinib versus crizotinib in advanced ALK inhibitor–naive ALK-positive non–small cell lung cancer: second interim analysis of the phase III ALTA-1L trial

DR Camidge, HR Kim, MJ Ahn, JCH Yang… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor,
demonstrated superior progression-free survival (PFS) and improved health-related quality …

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label …

YL Wu, Y Cheng, X Zhou, KH Lee, K Nakagawa… - The Lancet …, 2017 - thelancet.com
Background Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor.
We compared its efficacy and safety with that of the reversible EGFR tyrosine kinase inhibitor …

Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung …

Y Shi, G Chen, X Wang, Y Liu, L Wu, Y Hao… - The Lancet …, 2022 - thelancet.com
Background Furmonertinib (AST2818) is an irreversible, selective, third-generation EGFR
tyrosine-kinase inhibitor. We aimed to investigate the efficacy and safety of furmonertinib …

Poziotinib in Non–Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial

X Le, R Cornelissen, M Garassino… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE Insertion mutations in Erb-b2 receptor tyrosine kinase 2 gene (ERBB2 or HER2)
exon 20 occur in 2%-5% of non–small-cell lung cancers (NSCLCs) and function as an …

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

BJ Solomon, T Mok, DW Kim, YL Wu… - … England Journal of …, 2014 - Mass Medical Soc
Background The efficacy of the ALK inhibitor crizotinib as compared with standard
chemotherapy as first-line treatment for advanced ALK-positive non–small-cell lung cancer …

[HTML][HTML] The official French guidelines to protect patients with cancer against SARS-CoV-2 infection

B You, A Ravaud, A Canivet, G Ganem… - The Lancet …, 2020 - thelancet.com
On request of the French Health Ministry, the French High Council for Public health (Haut
Conseil de Santé Publique [HCSP]) entrusted a representative group of French medical …

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6) …

YL Wu, C Zhou, CP Hu, J Feng, S Lu, Y Huang… - The lancet …, 2014 - thelancet.com
Background Afatinib—an oral irreversible ErbB family blocker—improves progression-free
survival compared with pemetrexed and cisplatin for first-line treatment of patients with …